Tarsus Pharmaceuticals

NasdaqGS:TARS Stock Report

Mkt Cap: US$464.4m

Tarsus Pharmaceuticals Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Bobby Azamian

5.83yrs

Tenure

US$6,870,723

Compensation

Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016, Chief Executive Officer since September 2018 and s...


CEO Compensation Analysis

Bobby Azamian's Compensation vs Tarsus Pharmaceuticals Earnings
How has Bobby Azamian's remuneration changed compared to Tarsus Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$7mUS$550k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$3mUS$437k

-US$27m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$416kUS$300k

-US$5m

Compensation vs Market: Bobby's total compensation ($USD6.87M) is above average for companies of similar size in the US market ($USD2.84M).

Compensation vs Earnings: Bobby's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TARS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: TARS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.